VAValentina V. Algaizina

Valentina V. Algaizina

*This is an algorithmically generated author record based on publicly available information.

Valentina V. Algaizina has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Prospective study of pharmacogenetics and pharmacokinetics of bedaquiline in patients with drug-resistant pulmonary tuberculosis

    by Atadzhan E. Ergeshov, Alexander L. Khokhlov, Andrey V. Zakharov, Oksana G. Komissarova, Nikita V. Chumovatov, Vladimir V. Eremeev, Galina S. Shepelkova, Valentina V. Algaizina, Vladimir V. Romanov, Vladislav N. Turenko, et al.

    Background. Among the factors contributing to unsuccessful treatment outcomes in patients with drug-resistant pulmonary tuberculosis-particularly multidrug-resistant tuberculosis (MDR-TB)-considerable importance is attributed to interindividual variability in pharmacological response, which is largely determined by patients’ genetic characteristics. Recent advances in MDR-TB chemotherapy are closely associated with the introduction of bedaquiline. Bedaquiline is primarily metabolized by the cytochrome P450 enzyme CYP3A4; however, the impact of CYP3A4 gene polymorphisms on bedaquiline pharmacokinetics and treatment efficacy in patients with drug-resistant TB remains insufficiently studied. Personalized therapy based on a patient’s genetic profile represents a key strategy for optimizing dosing regimens, improving treatment efficacy, and reducing the risk of developing further drug resistance. Aims — to evaluate the influence of CYP3A4 polymorphic alleles (*1B/rs2740574 and *1G/rs2242480) on bedaquiline pharmacokinetic parameters and chemotherapy efficacy in patients with drug-resistant pulmonary tuberculosis, including those with MDR-TB. Methods. A prospective, observational cohort study was conducted involving 143 patients with pulmonary tuberculosis and confirmed drug-resistant Mycobacterium tuberculosis (including MDR, pre-XDR, and XDR-TB) treated at the Central TB Research Institute (CTRIT), Russia, between 2022 and 2024 (66 women and 77 men). Three observation groups were formed based on genotype: Group 1 — wild-type CYP3A4*1 (n = 99); Group 2 — *1B (rs2740574) carriers (n = 10); Group 3 — *1G (rs2242480) carriers (n = 34). Genotyping was performed using polymerase chain reaction–restriction fragment length polymorphism (PCR-RFLP). Bedaquiline was administered as part of individualized chemotherapy regimens at a dose of 400 mg once daily for 2 weeks, followed by 200 mg three times weekly for up to 6 months. Bedaquiline pharmacokinetic parameters were assessed in 30 patients using high-performance liquid chromatography. Treatment efficacy was evaluated based on sputum culture conversion by month 6. Statistical analysis employed nonparametric Kruskal–Wallis and Mann–Whitney tests for group comparisons. Results. Patients carrying the CYP3A4 *1G (rs2242480) allele showed significantly higher bedaquiline exposure compared to wild-type individuals: AUC₀–₂₄ (49.06 vs. 41.99 µg·h/mL; p 0.05), Cmax (3.13 vs. 2.21 µg/mL; p 0.05), and AUC₀–₂₄/MIC ratio (196.24 vs. 167.94; p 0.05), suggesting reduced metabolic clearance. In contrast, the *1B variant was associated with lower AUC₀–₂₄. Although culture conversion rates at 6 months did not differ significantly (p = 0.87), a trend toward higher efficacy was observed in *1G carriers (95.8%) versus wild-type patients (84.5%). Conclusion. The CYP3A4 *1G (rs2242480) polymorphism is associated with decreased bedaquiline metabolism, leading to increased systemic drug exposure and a potential improvement in treatment response. These findings highlight the role of CYP3A4 genetics in bedaquiline pharmacokinetics and support the integration of CYP3A4 genotyping into personalized MDR-TB treatment strategies. The *1G allele may serve as a promising pharmacogenetic biomarker for optimizing bedaquiline dosing in drug-resistant tuberculosis.

  • Evaluation of the efficacy, safety, and cost-effectiveness of clofazimine in the treatment of drug-resistant tuberculosis: a systematic review

    by Alexey M. Tikhonov, Sergey A. Pavlov, Andrey V. Zakharov, Violetta A Shorokhova, Valentina V Algazina, Vladimir V. Romanov

    Currently, new chemotherapy regimens for drug-resistant tuberculosis are being actively introduced into phthisiat-ric practice around the world, using new and promising chemotherapy drugs. Objective: to evaluate the efficacy, safety, and economic feasibility of clofazimine in the treat-ment of drug-resistant tuberculosis based on data from randomized clinical trials, cohort studies, and observation-al studies. Methods. In preparation for the publication, a search was conducted in the PubMed, Web of Science, and EMBASE databases for studies published before Ja-nuary 1, 2025. An analysis was conducted of published randomized controlled trials, cohort studies, and obser-vational studies comparing treatment regimens for multi-drug-resistant TB with and without clofazimine, as well as regimens with other drugs (bedaquiline, linezolid, and delamanid). The study evaluated the efficacy (sputum cul-ture conversion, treatment success), safety (frequency and types of adverse events), and economic feasibility (drug costs, treatment duration, and indirect costs). Results. Clofazimine shows significant efficacy in TB treatment regimens with various types of drug resistance, not limited to MDR TB, but also demonstrating potential for XDR TB. The drug significantly accelerates the conversion of spu-tum culture and increases the success rates of treatment. Clofazimine is generally well-tolerated in the treatment of drug resistance ТB, but its use is associated with specific, manageable adverse events (AE). The most common AE are skin discoloration (up to 94.3% of patients) and ichthy-osis (47.2%). Clofazimine-based regimens have significant cost-effectiveness due to reduced treatment duration and improved resource utilization in low-income settings. Studi-es show that clofazimine-containing regimens can reduce the treatment duration for MDR TB from 18–24 months to 9 months, which reduces healthcare costs and patient burden. Conclusion. Clofazimine demonstrates significant efficacy, safety, and cost-effectiveness in the treatment of drug-resistant TB, especially in resource-constrained set-tings. It has a predictable safety profile, but requires ECG monitoring when co-prescribed with other QT-prolonging drugs. Its use is cost-effective as part of a strategy to imple-ment shorter treatment regimens.